Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The plan is to advance innovative therapies to drug-resistant cancers
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Subscribe To Our Newsletter & Stay Updated
